Health Care · Pharmaceutical Preparations

TNGX Tango Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 181913390 filings
Russell 2000

TNGX at a glance

Tango Therapeutics, Inc. (TNGX, SEC CIK 1819133) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Tango Therapeutics, Inc. (TNGX) reported revenue of $62.4 million (up 48.3% from FY2024) and a net loss of $101.6 million. Diluted EPS was -$0.87.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Tango Therapeutics, Inc. (TNGX) shares worth $1.4 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Ketchum John B on November 17, 2026 of 3,333 shares at $24.08 per share.
  • In the last 90 days, TNGX insiders reported 0 open-market purchases ($0) and 12 open-market sales ($1.9M) on Form 4, a net sale of $1.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$62.4M
+48.3% vs prior year
Insiders · 90 days
0 buys · 12 sells
Net −$1.9M
13F holders
30 funds
$1.4B · +1 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026
  • Macroeconomic exposure: Cash runway of $343.1M as of Dec 31, 2025 expected to fund operations only into 2028, requiring substantial additional capital raises
  • Operational vulnerability: Dependence on third-party CROs and manufacturers for preclinical and clinical trial execution and drug supply management
  • Competitive risk: Combination therapy trials with Revolution Medicines’ RAS inhibitors and Erasca’s ERAS-0015 molecular glue amid oncology market competition
  • Financial risk: Net losses averaging ~$111M in 2025 with accumulated deficit $603.2M, no current product revenue, reliance on equity financing and collaboration revenue

AI summary of the TNGX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New combination-supply risk: daraxonrasib supply uncertainty threatens planned global registrational trial in first half of 2027
  • Regulatory risk: third-party combination drugs may lack regulatory approval or remain unavailable for clinical and commercial use
  • Operational risk: failure to secure daraxonrasib could delay development timelines
  • Financial risk: purchasing checkpoint inhibitors or comparator therapies may increase development costs
  • Partnership risk: loss of collaborations with Revolution Medicines, Lilly, or Erasca could disrupt combination trials

Management Discussion & Analysis

  • Quarterly collaboration revenue $0, down $53.8M YoY from Gilead recognition
  • Net loss $68.4M vs net income $15.9M YoY; operating margin not disclosed
  • Vopimetostat plus daraxonrasib: 82% ORR and 88% nine-month PFS in 22 PDAC patients
  • Cash, equivalents and marketable securities $977.5M; operating cash use $120.4M through nine months
  • Outlook: $977.5M funds operations at least twelve months; registrational trial expected first half 2027

AI summary of the TNGX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Tango Therapeutics’ quarter ended September 30, 2026
  • Exhibit 99.1 contains the company’s operating results and financial condition update

Item EX-99.1: Item EX-99.1

  • Phase 1/2 combination data showed 82% ORR and 88% nine-month PFS in 2L/3L pancreatic cancer
  • Phase 3 front-line MTAP-deleted pancreatic cancer study planned for 1H 2027, with ORR and PFS as primary endpoints
Filed Oct 23, 2026Full analysis →

Item 8.01: Other Events

  • Daraxonrasib combination showed 82% ORR and 88% 9-month PFS in 22 efficacy-evaluable second- or third-line PDAC patients
  • Dose level 1 safety generally manageable, but 40% Grade 3 TRAEs and dose level 2 produced 3 DLTs in 2 patients

Item EX-99.2: Item EX-99.2

  • PDAC update highlights 82% ORR and 88% 9-month PFS for vopimetostat plus daraxonrasib in MTAP-deleted disease
  • Phase 3 first-line trial planned for 1H 2027, targeting 484 patients with dual ORR and PFS primary endpoints

Item EX-99.1: Item EX-99.1

  • Phase 1/2 PDAC data: 82% ORR, 88% 9-month PFS, and 100% disease control in 22 efficacy-evaluable patients
  • Planned global Phase 3 in front-line MTAP-deleted PDAC targets 1H 2027, with ORR and PFS primary endpoints

Item 7.01: Regulation FD Disclosure

  • Updated Phase 1/2 trial results for vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors
  • Results cover an ongoing clinical program, making emerging efficacy and safety data material to TNGX valuation
Filed Aug 11, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Tango Therapeutics’ results for quarter ended June 30, 2026
  • Exhibit 99.1 contains the company’s operating results and financial-condition details

Item EX-99.1: Item EX-99.1

  • Q2 2026 revenue $0; net loss $55.3M, or $0.37 per share, versus $38.9M and $0.35 previously
  • Cash, equivalents and marketable securities $1.0B, supporting planned Phase 3 advancement and commercialization preparation

AI summaries of TNGX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TNGX

Don't miss the next TNGX filing

  • Alerts as it files. A push when TNGX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TNGX, by share count.
  • Ask anything. An AI agent that reads every TNGX filing and answers with sources.

TNGX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Ketchum John BSellNov 17, 2026$24.08
Crystal AdamMNov 11, 2026-
Crystal AdamMNov 11, 2026$2.91
Crystal AdamSellNov 11, 2026$25.00
Newcomb JessicaSellNov 2, 2026$22.98
Newcomb JessicaSellNov 2, 2026$22.28
Crystal AdamSellNov 2, 2026$22.26
Crystal AdamSellNov 2, 2026$22.99

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$42.1M$62.4M
Operating Income--$145.6M-$111.3M
Net Income-$101.7M-$130.3M-$101.6M
Op. Margin--346.1%-178.4%
Net Margin--309.7%-162.9%
Balance Sheet
Total Assets$402.6M$316.5M$398.7M
Equity-$199.5M$346.2M
ROE--65.3%-29.3%
Per Share
EPS$-1.08$-1.19$-0.87
Cash Flow
Operating CF--$131.5M-$138.9M
CapEx$1.5M$754K$1.0M

Source: XBRL data in Tango Therapeutics, Inc. (TNGX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TNGX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TNGX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$1.41B
Q2 202629$2.01B
Q1 202627$884.2M
Q4 202521$312.9M
Q3 202524$222.2M
Q2 202524$103.4M
Q1 202524$19.5M
Q4 202419$42.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TNGX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 13, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Nov 4, 2026--
4Nov 4, 2026--
8-KOct 23, 2026Analysis-
4Oct 5, 2026--
4Sep 24, 2026--
4Sep 3, 2026--
SC 13GAug 14, 2026-
10-QAug 11, 2026Analysis
8-KAug 11, 2026Analysis-
8-KAug 11, 2026Analysis-
8-KAug 7, 2026Analysis-
8-KAug 6, 2026Analysis-
4Aug 5, 2026--
8-KJun 23, 2026Analysis-
4Jun 23, 2026--
8-KJun 10, 2026Analysis
4Jun 8, 2026-
8-KJun 8, 2026Analysis
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-

Related Health Care companies

All Health Care →

TNGX SEC filings: frequently asked questions

Are TNGX insiders buying or selling?

In the last 90 days, Tango Therapeutics, Inc. (TNGX) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $1.9 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TNGX stock?

As of September 30, 2026, the largest Tango Therapeutics, Inc. (TNGX) holders among the 13F filers tracked by SignalX were BlackRock ($327.9 million), Goldman Sachs Group ($284.7 million), State Street Corp ($182.5 million), Vanguard Capital Management LLC ($162.6 million), T. Rowe Price Group ($158.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TNGX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Tango Therapeutics, Inc. (TNGX) reported revenue of $62.4 million (up 48.3% from FY2024) and a net loss of $101.6 million. Diluted EPS was -$0.87. The figures come from the XBRL data in the 10-K.

What are the main risks in TNGX's latest 10-K?

In the 10-K filed March 5, 2026, Tango Therapeutics, Inc. (TNGX) flagged: Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026. Macroeconomic exposure: Cash runway of $343.1M as of Dec 31, 2025 expected to fund operations only into 2028, requiring substantial additional capital raises. (AI summary of the Risk Factors section.)

What did TNGX report in its latest 8-K?

Tango Therapeutics, Inc. (TNGX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Tango Therapeutics’ quarter ended September 30, 2026.

What are the latest TNGX SEC filings?

Tango Therapeutics, Inc. (TNGX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 19, 2026.

What is TNGX's SEC CIK number?

Tango Therapeutics, Inc. (TNGX)'s SEC Central Index Key (CIK) is 1819133. EDGAR lists every TNGX filing under that number.

Ask anything about TNGX

The research agent reads TNGX's filings, financials, insider trades and 13F holders, then answers with sources.